Results 21 to 30 of about 8,268,208 (290)

Complexed Prostate-specific Antigen and the “Prostate-specific Antigen Gap” [PDF]

Clinical Chemistry, 1999
Jung et al. (1) reported an apparent gap between total serum prostate-specific antigen (t-PSA) and the sum of free PSA (f-PSA) plus α1-antichymotrypsin-PSA (ACT-PSA) in patients with prostate carcinoma (PCa) but not in those with benign prostatic hypertrophy (BPH).
Iain S Ross, Nicholas P Cohen, Patrica A Duff, Arthur Dickie, Ian Mitchell, Bernard L Croal   +5 more
openaire   +1 more source

Prostate Specific Antigen [PDF]

American Journal of Clinical Pathology, 2006
Prostate cancer is a highly prevalent disease that is characterized by a wide range of aggressiveness, ranging from the clinically irrelevant to the rapidly progressive, lethally metastatic. Since its introduction as a serum test in the late 1980s, prostate-specific antigen (PSA) has been increasingly promulgated as an important biomarker for prostate ...
Kristin R. Swanson, Hana L.P. Harpold, Lawrence D. True   +2 more
  +5 more sources

Prevention and early detection of prostate cancer. [PDF]

, 2014
Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer.
Culig, Zoran, Vecchia, Carlo La, Stenzl, Arnulf, P. H. Brown, Meyskens, FL, H. Schmid, Thorat, M.A., Parnes, Howard L., Wilt, Timothy J, Rittenhouse, H., Minasian, Lori M, Perner, S. (Sven), Schmid, H-P, Cuzick, J, Minasian, LM, Brawley, Otis W., Ford, Leslie G., G. Andriole, Perner, S, Key, Timothy J., D. Ilic, Ilic, Dragan, Parker, C. (C.), Key, TJ, Andriole, Gerald, Hamdy, Freddie C., R. A. Eeles, Holmberg, Lars, J. Schalken, Eeles, R. (Rosalind), Parker, C, Lilja, Hans, Wolk, Alicja, Holmberg, Lars,, Parnes, Howard L, Tombal, B, T. J. Wilt, Schmitz-Dräger, Bernd J., Schmitz-Draeger, BJ, F. H. Schröder, Hamdy, Freddie C, F. C. Hamdy, Lilja, H, Marberger, Michael, Lund University., Hamdy, FC, Schalken, J, Andriole, G.L. (Gerald), Andriole, G, Cuzick, Jack, Hamdy, F. (Freddie), Schmid, HP, Vecchia, C. La, Schmid, Hans Peter, Ford, L.G., A. Wolk, Tombal, Bertrand, Schmid, H.P., Meyskens, F.L. (Frank L), Wilt, TJ, Schmid, H.-P. (Hans-Peter), Thorat, Mangesh A, Brawley, O.W., T. J. Key, Lilja, H., Schalken, J.A. (Jack), Parker, C., Holmberg, L, Schmitz-Dräger, Bernd J, M. Marberger, La Vecchia, C, Key, T.J. (Timothy J), Brawley, OW, F. L. Meyskens, Eeles, Rosalind A, Schröder, F.H. (Fritz), B. J. Schmitz Dräger, Brown, PH, Parker, Chris, Ilic, D, Ilic, D. (Dragan), Ford, L.G. (Leslie G), C.La Vecchia, Wolk, K. (Kerstin), Tombal, B. (Bertrand), Schmitz-Drager, B.J., Minasian, L.M. (Lori M), L. M. Minasian, Schröder, Fritz H, H. Lilja, B. Tombal, Schalken, J.A., Brown, Powel H, Rittenhouse, H. (Harry), O. W. Brawley, Stenzl, A, C. Parker, Brawley, O.W. (Otis W), Meyskens, Frank L., Vecchia, C.L. (Carlo La), Culig, Z., Brown, P.H., Parnes, HL, Cuzick, J., Wilt, Timothy J., Ford, Leslie G, Z. Culig, Culig, Z. (Zoran), L. G. Ford, Brawley, Otis W, Key, Timothy J, Schmitz-Dräger, B.J. (Bernd J), S. Perner, Marberger, M, Schalken, Jack, Thorat, M.A. (Mangesh A), Hamdy, F.C., Stenzl, A. (Arnulf), Wilt, T.J., Wolk, A, Schroder, F.H., Culig, Z, Key, T.J., Eeles, R.A., Lilja, Hans,, Ford, LG, Lilja, H. (Hans), Parnes, H.L. (Howard L), Eeles, RA, Marberger, M., Andriole, G., Schröder, Fritz H., Schmid, Hans-Peter, Stenzl, A., L. Holmberg, Meyskens, F.L., Thorat, Mangesh A., A. Stenzl, Meyskens, Frank L, Brown, P.H. (Powel H), J. Cuzick, La Vecchia, Carlo, H. Rittenhouse, H. L. Parnes, Wolk, A., Rittenhouse, Harry, Perner, Sven, M. A. Thorat, Tombal, B., Schröder, Fritz, Minasian, Lori M., Ilic, D., Minasian, L.M., Parnes, H.L., Rittenhouse, H, Marberger, M. (Michael), Perner, S., Holmberg, L. (Lars), Cuzick, J. (Jack), Wilt, T.J. (Timothy J.), Holmberg, L., Thorat, MA, Eeles, Rosalind A., Brown, Powel H., Marberger M, Schmid HP, Wolk A, Cuzick J, Eeles RA, Ford LG, Ilic D, Key TJ, Stenzl A, Thorat MA, Schalken J, Hamdy FC, Parnes HL, Holmberg L, Schröder FH, Minasian LM, Parker C, Brawley OW, Andriole G, Culig Z, Schmitz-Dräger BJ, Lilja H, Rittenhouse H, La Vecchia C, Tombal B, Perner S, Wilt TJ, Meyskens FL, Brown PH, Schroder, FH, Schmitz-Drager, BJ   +194 more
core   +1 more source

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS

Jurnal Urologi Indonesia, 2016
Objective: In Hasan Sadikin General Hospital Bandung prostate biopsy is recommended for patients with prostate specific antigen (PSA) levels above 10 ng/mL or PSA density (PSAD) above 0.15 if PSA in between 4–10 ng/mL.
Daniel Simanjuntak, Ferry Safriadi
doaj   +1 more source

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer

Prostate International, 2013
Racial differences exist in the incidence of prostate cancer (PCa). Although many studies have looked at the performance of prostate-specific antigen (PSA) and PSA density (PSAD) in the detection of PCa, only a few have looked at it in relation to ...
Ahmad Anies Shahab, Doddy M. Soebadi, Wahjoe Djatisoesanto, Sunaryo Hardjowijoto, Soetojo Soetojo, Lukman Hakim   +5 more
doaj   +1 more source

PROSTATE-SPECIFIC ANTIGEN VELOCITY AND REPEATED MEASURES OF PROSTATE-SPECIFIC ANTIGEN

Urologic Clinics of North America, 1997
Numerous studies evaluating different populations have shown similar findings with respect to repeated PSA measurements and PSAV. First, there is substantial within-individual variability between repeated PSA measures. Second, this variability between PSA measurements precludes the use of a simple change in PSA as a marker for prostate cancer.
H B, Carter, J D, Pearson
openaire   +2 more sources

Glycotyping of prostate specific antigen [PDF]

Glycobiology, 2000
Measurement of serum levels of the prostate specific antigen (PSA) is now widely used for the diagnosis of prostate cancer and benign prostate hyperplasia. This serum marker is of value since it is derived only from the tissue of interest, but increased levels of PSA in serum do not allow a completely clear cut diagnosis of benign versus malignant ...
S, Prakash, P W, Robbins
openaire   +2 more sources

Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience

, 2023
Objective: Lutetium-177 prostate-specific membrane antigen-617 is a novel alternative therapeutic option in metastatic castration-resistant prostate cancer, especially useful for patients who do not respond to standard therapy methods.
Maman, Adem, Adem Maman
core   +1 more source

Western Blotting Analysis of Antibodies to Prostate-Specific Antigen: Specificities for Prostate-Specific Antigen and Prostate-Specific Antigen Fragments

Tumor Biology, 1999
Approximately 40% of the prostate-specific antigen (PSA) purified from seminal fluid comprises cleaved or fragmented forms of PSA. These fragments are observed by reduced SDS-PAGE and have been identified in preparations of purified seminal plasma. The comparative analysis of 53 antibodies, submitted to an international PSA Workshop, with different PSA
T J, Wang, H J, Linton, R L, Sokoloff, L S, Grauer, H G, Rittenhouse, R L, Wolfert   +5 more
openaire   +2 more sources

Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia

Asian Journal of Andrology, 2015
In Western countries, clinical trials on prostate cancer screening demonstrated a limited benefit for patient survival. In the Asia-Pacific region, including Japan, the rate of prostate-specific antigen (PSA) testing remains very low compared with ...
Yasuhide Kitagawa, Mikio Namiki
doaj   +1 more source